Company Overview and News
The Dow lost as much as 250 points, or about 1%, on Thursday after the White House scrapped the June 12 meeting in Singapore. The S&P 500 and Nasdaq fell nearly 1% apiece. All three major indexes rebounded before long and were down just modestly by early afternoon.
(Reuters) - A U.S. threat that it may introduce tariffs on foreign auto imports drew strong criticism on Thursday from the country’s main business lobbying group, which warned of a “staggering” blow to the industry and the prospect of a global trade war.
Adding fuel to the ongoing trade tensions, the Trump administration has initiated a national security investigation into auto imports that may result in fresh tariffs. And U.S. President Donald Trump’s urging that any deal would need “a different structure” has stirred global trade worries all over again.
A decline in energy shares following lower oil prices also weighed on the market, with the S&P energy index ending down 1.7 per cent.
US stocks ended down slightly on Thursday after President Donald Trump canceled a planned summit with North Korea's Kim Jong Un and threatened to impose tariffs on auto imports, though losses were limited by gains in Netflix and General Electric.
Worries over U.S. trade protectionism, this time around car imports, weighed on Wall Street's main indexes on Thursday, overshadowing optimism that the Federal Reserve may be more tolerant of rising inflation than previously expected.
A Trump administration investigation of car and truck imports raised the threat on Thursday of renewed conflict over trade policy for an industry that thrives on stability and sent stocks in Asian and European automakers down.
Shares of General Motors and Ford inched only marginally higher before the bell on Thursday after the Trump administration launched a national security probe into car imports which could lead to new tariffs on foreign competitors while also stirring trade tensions.
The United Auto Workers International Union (UAW) has filed a complaint accusing Tesla Inc Chief Executive Elon Musk of illegally threatening to take away benefits from workers who join the union.
This copy is for your personal non-commercial use only. To order presentation-ready copies of Toronto Star content for distribution to colleagues, clients or customers, or inquire about permissions/licensing, please go to: www.TorontoStarReprints.com
As testimony to easing trade tensions with the United States, China slashed import tariffs for automobiles and car parts effective Jul 1. The import duties have been reduced from 25% to 15% for vehicles and from 10% to 6% for auto parts including bumpers, doors, and seat belts. The auto tariff is still higher than the 2.5% U.S. charges on imported cars but less than the 25% charged by Washington on imported pickup trucks (read: Auto ETFs & Stocks Worth Buying Despite Weak April Sales).
NEW YORK (AP) — Five months after massive federal tax changes became law, many small business owners still don't know whether they'll be winners or losers.
Markets ended lower on Tuesday erasing early gains, after President Donald Trump said that he wasn’t satisfied with the progress of United States-China trade talks. Moreover, Trump also said that the highly awaited summit between the United States and North Korea might not happen at all.
Given the popularity of pickups and sport utility vehicles in the United States since the price of gasoline dropped sharply, along with the price of oil, a few years ago, it is little wonder that U.S. automakers are not well represented on Kelley Blue Book’s latest list of the 10 coolest cars under $20,000 for 2018.
The Dow Jones Industrial Average fell 178.88 points, or 0.72 per cent, at 24,834.41, the S&P 500 lost 8.57 points, or 0.31 per cent, to 2,724.44 and the Nasdaq Composite dropped 15.58 points, or 0.21 per cent, to 7,378.46.
2018-05-25 - Asif
Overview Heron is a commercial-stage biotechnology company focused on improving the lives of patients by developing best-in-class treatments that address some of the most important unmet patient needs. Heron Therapeutics is developing novel, patient-focused solutions that apply its innovative science and technologies to already approved pharmacological agents for patients suffering from cancer or pain. On August 9, 2016, its first commercial product, SUSTOL, was approved by the FDA. The company developed SUSTOL for the prevention of chemotherapy-induced nausea and vomiting (“CINV”). SUSTOL is indicated, in combination with other antiemetics, in adults for the prevention of acute and delayed nausea and vomiting associated with initial and repeat courses of moderately emetogenic chemotherapy (“MEC”) or anthracycline and cyclophosphamide (“AC”) combination chemotherapy regimens. The company commenced commercial sales of SUSTOL in the U.S. in October 2016. On November 9, 2017...
2018-05-25 - Asif
Overview The company's mission is to deliver high-speed coherent optical interconnect products that transform communications networks, relied upon by cloud infrastructure operators and content and communication service providers, through improvements in performance and capacity and reductions in associated costs. By converting optical interconnect technology to a silicon-based technology, a process the company refer to as the siliconization of optical interconnect, the company believe Acacia Communications is leading a disruption that is analogous to the computing industry’s integration of multiple functions into a microprocessor. The company's products include a family of low-power coherent digital signal processor application-specific integrated circuits, or DSP ASICs, and silicon photonic integrated circuits, or silicon PICs, which Acacia Communications has integrated into families of optical interconnect modules with transmission speeds ranging from 100 to 400 gigabits per ...
2018-05-21 - Asif
Overview Anthera Pharmaceuticals, Inc. is a biopharmaceutical company focused on advancing the development and commercialization of innovative medicines that benefit patients with unmet medical needs. The company currently have two compounds in development, Sollpura and blisibimod. The company licensed Sollpura from Eli Lilly & Co (“Eli Lilly”) in July 2014. Sollpura is a novel non-porcine investigational Pancreatic Enzyme Replacement Therapy (“PERT”) intended for the treatment of patients with Exocrine Pancreatic Insufficiency (“EPI”), often seen in patients with cystic fibrosis and other conditions. The company licensed blisibimod from Amgen, Inc. (“Amgen”) in December 2007. Blisibimod targets B-cell activating factor, or BAFF, which has been shown to be elevated in a variety of B-cell mediated autoimmune diseases, including Immunoglobulin A nephropathy, or IgA nephropathy. Sollpura The exocrine pancreas is responsible for synthesis and secretion of digestive en...
as of ET